Five Prime Thera Cmn (FPRX) 43.98 $FPRX Five Prime

New Post Public Reply Private Reply Replies (0) Message Board

Sep 1, 2016 at 1:12 AM

Five Prime Thera Cmn (FPRX) 43.98 $FPRX

Five Prime Announces Second Quarter 2016 Results and Provides Business Update
GlobeNewswire - Thu Aug 04, 3:06PM CDT
Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today provided a corporate update and reported financial results for the second quarter ended June 30, 2016.
FPRX: 43.98 (-2.27)

Research Report Initiation on These Biotech Stocks -- Tesaro, Cerus, Five Prime Therapeutics, and Intercept Pharma
PR Newswire - Thu Aug 04, 7:20AM CDT
The Biotech industry has been showing signs of strength in the previous days due to increased M&A activities and lesser regulatory and political pressures. On Tuesday, the iShares NASDAQ Biotechnology ETF rose to a high of $299 per share, as per CNBC. Stock-Callers.com takes a look at the following equities and see if they are poised for growth: Tesaro Inc. (NASDAQ: TSRO), Cerus Corp. (NASDAQ: CERS), Five Prime Therapeutics Inc. (NASDAQ: FPRX), and Intercept Pharmaceuticals Inc. (NASDAQ: ICPT). Learn more about these stocks by downloading their free report at:
CERS: 6.33 (-0.30), TSRO: 84.69 (-1.40), ICPT: 148.31 (-2.36), FPRX: 43.98 (-2.27)

Five Prime Therapeutics Presents Updated Data from Phase 1 trial of Single-Agent FPA144 at 2016 ASCO Annual Meeting
GlobeNewswire - Mon Jun 06, 8:25AM CDT
-- Initial data show a 33% confirmed objective response rate, 77% disease control rate, and 12-week progression free survival of 67% in 9 FGFR2b+ gastric cancer patients available for analysis
FPRX: 43.98 (-2.27)

Five Prime Therapeutics Announces Updated Data in Mesothelioma Patients from Ongoing Phase 1b Trial of FP-1039 Presented at 2016 ASCO Annual Meeting
GlobeNewswire - Sat Jun 04, 8:24AM CDT
-- Objective response rate of 39% and disease control rate of 100% in patients at or below the maximum tolerated dose level; progression free survival of 6.8 months, though data are still maturing
FPRX: 43.98 (-2.27)

Five Prime Therapeutics to Present at the Jefferies 2016 Healthcare Conference
GlobeNewswire - Thu Jun 02, 8:30AM CDT
Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today announced that Robert Sikorski, MD, PhD, Chief Medical Officer, will present at the Jefferies 2016 Healthcare Conference on Wednesday, June 8, 2016, at 2:30 PM Eastern Daylight Time.
FPRX: 43.98 (-2.27)

Five Prime Therapeutics Appoints Dr. Robert Sikorski as Chief Medical Officer
GlobeNewswire - Wed Jun 01, 3:05PM CDT
Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today announced the appointment of Robert Sikorski, M.D., Ph.D., to chief medical officer. In this role, he will oversee all clinical development (including clinical operations, pharmacovigilance, pharmacokinetics and biostatistics) and regulatory affairs, and will play a leading role in advancing Five Prime's immuno-oncology portfolio.
FPRX: 43.98 (-2.27)

How Well are These Healthcare Stocks Performing? - Radius Health, Cerus, Arrowhead Pharma, and Five Prime Therapeutics
PR Newswire - Thu May 26, 7:50AM CDT
Despite the volatility that continues to envelop the Biotech industry, investors see value in this space. Today's pre-market research on ActiveWallSt.com directs the investor community's focus on the following Healthcare equities: Radius Health Inc. (NASDAQ: RDUS), Cerus Corp. (NASDAQ: CERS), Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR), and Five Prime Therapeutics Inc. (NASDAQ: FPRX). Register with us today for these stock technical briefings at:
CERS: 6.33 (-0.30), RDUS: 54.84 (-0.67), ARWR: 6.93 (-0.15), FPRX: 43.98 (-2.27)

Five Prime Therapeutics Announces Updated Clinical Data on FPA144 and FP-1039 to be Presented during 2016 ASCO Annual Meeting
GlobeNewswire - Wed May 18, 4:00PM CDT
Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, announced that updated data from the ongoing clinical trials of FPA144 and FP-1039 will be presented during the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting to be held June 3-6, 2016, in Chicago. The presentation abstracts are now available online at the meeting website: https://iplanner.asco.org/am2016/#/. Information contained in the abstracts was as of the time of submission in February 2016. Five Prime intends to announce more detailed results at the time of the presentations at the ASCO Annual Meeting.
FPRX: 43.98 (-2.27)

Five Prime Therapeutics Advances FPA008 Into Phase 2 Dose Expansion in Patients with Pigmented Villonodular Synovitis (PVNS)
GlobeNewswire - Thu May 12, 8:00AM CDT
Five Prime Therapeutics, Inc. (Nasdaq:FPRX) a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced the advancement of FPA008 into the Phase 2 dose expansion portion of the ongoing Phase 1/2 trial in PVNS.
FPRX: 43.98 (-2.27)

Five Prime Therapeutics posts 1Q loss
Automated Insights - Thu May 05, 6:12PM CDT
SOUTH SAN FRANCISCO, Calif. (AP) _ Five Prime Therapeutics Inc. (FPRX) on Thursday reported a loss of $13 million in its first quarter.
FPRX: 43.98 (-2.27)

Five Prime Therapeutics to Announce First Quarter 2016 Financial Results and Host Conference Call on May 5
GlobeNewswire - Thu Apr 21, 3:05PM CDT
Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, will report its first quarter 2016 financial results on Thursday, May 5, 2016, after the U.S. financial markets close. Five Prime will host a conference call and live audio webcast on Thursday, May 5, 2016, at 5:00 p.m. (ET)/2:00 p.m. (PT) to discuss the company's financial results and provide a general business update.
FPRX: 43.98 (-2.27)

Top 4 Sales Growth Stocks
Zacks Equity Research - Zacks Investment Research - Mon Apr 18, 12:25PM CDT
Sales growth is an important indicator of a company's health and ability to sustain its business.
GILD: 78.38 (+0.46), TROW: 69.54 (-0.36), RMD: 66.69 (-0.53), FPRX: 43.98 (-2.27)

Five Prime Therapeutics Announces New Pre-Clinical Data on FPA144 Presented at the 2016 AACR Annual Meeting
GlobeNewswire - Mon Apr 18, 8:00AM CDT
-- Engineering of FPA144 for ADCC drives both innate and adaptive responses
FPRX: 43.98 (-2.27)

Looking for a Top Momentum Stock? 3 Reasons Why Five Prime Therapeutics (FPRX) is a Great Choice
Zacks Equity Research - Zacks Investment Research - Tue Apr 12, 7:28AM CDT
Five Prime Therapeutics is a great momentum stock and has been witnessing positive activity in the earnings estimate revision front as well
FPRX: 43.98 (-2.27)

Five Prime Therapeutics Announces FPA144 Will Be Featured During a Special Session at the 2016 AACR Annual Meeting
GlobeNewswire - Mon Apr 11, 3:05PM CDT
Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, announced that it will present the FPA144 program during a special session at the 2016 American Association for Cancer Research (AACR) Annual Meeting, being held April 16-20 in New Orleans.
FPRX: 43.98 (-2.27)

Can the Rally in Five Prime Therapeutics (FPRX) Shares Continue?
Zacks Equity Research - Zacks Investment Research - Fri Apr 08, 7:27AM CDT
Five Prime Therapeutics Inc (FPRX) has been on the move lately as the stock has risen by 38.2% in the past four weeks, and it is currently trading well above its 20-Day SMA
FPRX: 43.98 (-2.27)

Five Prime Therapeutics to Present at the 2016 Jefferies Immuno-Oncology Summit
GlobeNewswire - Fri Apr 01, 3:05PM CDT
Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics for cancer and inflammatory diseases, today announced that Lewis T. "Rusty" Williams, M.D., Ph.D., Founder, Chief Executive Officer and Chairman of the Board, will present at the 2016 Jefferies Immuno-Oncology Summit on Friday, April 8, 2016, at 11:00 A.M. Eastern Daylight Time.
FPRX: 43.98 (-2.27)

Five Prime Therapeutics (FPRX) Looks Good: Stock Adds 5%
Zacks Equity Research - Zacks Investment Research - Wed Mar 30, 7:25AM CDT
Five Prime Therapeutics, Inc. (FPRX) saw its shares rise just over 5% on the day.
AMAG: 23.83 (-0.06), FPRX: 43.98 (-2.27)

Five Prime Therapeutics to Present at the LEERINK Partners 5th Annual Global Healthcare Conference
GlobeNewswire - Thu Feb 04, 3:08PM CST
Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that Aron Knickerbocker, Executive Vice President and Chief Business Officer, will present at the LEERINK Partners 5 Annual Global Healthcare Conference on Thursday, February 11, 2016 at 9:20 AM Eastern Standard Time.
FPRX: 43.98 (-2.27)

Five Prime Therapeutics Announces Key Executive Appointments
GlobeNewswire - Mon Feb 01, 3:05PM CST
-- Kevin Baker, Ph.D., appointed as Senior Vice President of Development Sciences
FPRX: 43.98 (-2.27)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Karen Love's Retirement Marks End of an Era for TACHP

A Legacy Not Just Built, But Carved in Stone In the world of healthcare, folks like Karen Love don’t come around too often. She's stepping down from her post as President and CEO of Cook Children's Health Plan this month, and it feels like the end of a chapter for the Texas Association of Community Health Plans (TACHP). Love wasn't just an executive; she was a mover and...

MiniCo's New Desk: A Game Changer for E&S Market

A New Chapter in Industrial Casualty Look out, folks! MiniCo Insurance Agency is making waves with its latest launch. They're teaming up with Lloyd's of London, not to sell fish and chips, but to bring something groundbreaking in the insurance space—an industrial casualty trading desk. And if you’re raising an eyebrow wondering why this matters, let me break it down...

Rochester Memorial Installations: Key Timelines Revealed

There are times in life where patience isn’t just a virtue, it’s a necessity—memorial installations are one of those instances. In Rochester, NY, folks dealing with the loss of a loved one want more than just closures; they want to commemorate their people in a way that lasts. But how long does it take, really, to set these tributes in stone? Understanding the...

New Tools Arm Manufacturers in Additive Arena

Diving Headfirst into Additive Manufacturing Standards Additive manufacturing (AM)—it's not just another tech buzzword. It's revolutionizing everything from life-saving medical devices to cutting-edge aerospace components. But as with any game-changing innovation, there's a wild west era before standards reign in the chaos. Enter ANSI and America Makes, offering new...

Hyundai's Record Q3 Sales: SUVs and Hybrids Lead

Hyundai's Drive to Record Q3 Sales When talking about market moves, Hyundai's recent figures speak louder than most quarterly bells. September 2026 marked a whirlwind of growth for Hyundai Motor America, reporting record-breaking sales numbers not just for the month, but for Q3 as a whole. With a 9% jump from September last year in total vehicle sales and a remarkable 3%...

Athlete Threats: Public Info Fuels Security Risks

Public Exposure: The New Athlete Achilles' Heel Imagine sitting on millions while living in a glass house. That's the kind of predicament today's athletes find themselves in, thanks to the treasure trove of public information spilling their personal lives all over the internet. According to the latest Hush Intelligence Athlete Threat Report 2026, this very exposure has...

Ace Hardware Ups the Stakes with Rewards Days Event

Ace Hardware: Doubling Down with Rewards Ace Hardware's rolling out the red carpet for its loyal customers. Imagine this: exclusive deals on trusted brands and double points on purchases—an incentive any savvy shopper would jump at. From October 6 to 7, those in the Ace Rewards circle have the chance to nab some hefty savings and perks, a move that's more than just a...

Gateway Unveils All-In-One Award Travel Platform

Transforming Loyalty with point.me's Gateway Here's the deal: the loyalty program game just changed. Point.me rolled out this slick beast called Gateway, and it's weaving award travel booking right into your everyday banking apps. That's right, ditch those clunky third-party sites, because now you can browse, compare, transfer, and book your award travel directly from...

Neutonic Sets Sights on U.S. with Walmart Expansion

Neutonic Embarks on Major Expansion with Walmart Well, here we go. Neutonic is stepping up to the big leagues by planting its flag in nearly 1,000 Walmart stores across the U.S. This move lands them right in the thrumming heart of Walmart's new Mood & Mind beverage set. It's about time this brand brings its functional beverages to American shoppers already drained by...

Texas A&M-San Antonio's Research Expansion Momentum

Texas A&M-San Antonio's Rising Research Ambitions A rainy day in San Antonio and Texas A&M University-San Antonio seems to have set the stage for more than just another semester of record enrollment. They’ve just rolled in with an exhilarating $8 million in external grants this fiscal year, more than doubling last year’s haul of $3.6 million, in a bid to push their...